Joan Bladé, Barcelona, Spain
Josep Maria Campistol, Barcelona, Spain
Amyloidosis: Classification and Epidemiology
Chair: Joan Bladé, Barcelona, Spain
Speaker: Per Westermark, Uppsala, Sweden
Basic Science: Amyloid Fibril Formation, Deposition and Clearance
Chairs:
John Berk, Boston, MA, USA
TBC
Amyloid fibril structures using cryo EM and ssNMR
Marcus Fändrich, Ulm, Germany
Structural basis of amyloidogenicity
Marina Ramírez-Alvarado, Rochester, MN, USA
Drivers of amyloid organ tropism and deposition
Gunilla Westermark, Uppsala, Sweden
Proteomics in the diagnosis of AL and ATTR amyloidosis
TBC
Proteotoxicity and organ damage
Francesca Lavatelli, Pavia, Italy
Intrinsec mechanisms of amyloid tissue clearance
Philip Hawkins, London, UK
Development of amyloid disruptors for ATTR amyloidosis
Mitsuharu Ueda, Kumamoto, Japan
AL amyloidosis: Diagnosis and Management in 2020
Chairs:
Ashutosh Wechalekar, London, UK
TBC
Diagnosis work-up and typing
Angela Dispenzieri, Rochester, MN, USA
Red-flags for early diagnosis
Ute Hegenbart, Heidelberg, Germany
New prognostic markers
Efstathios Kastritis, Athens, Greece
Cytogenetics in AL amyloidosis
Stefan Schönland, Heidelberg, Germany
Hematologic and organ response criteria
Giovanni Palladini, Pavia, Italy
Giampaolo Merlini Award and Lecture
Nomenclature Committee Meeting
A Deeper Look at ATTR-CM: An Under-recognized and Life-threatening Illness
Chairs:
Pablo García-Pavía, Madrid, Spain
Mechanisms and Patterns of Cardiac Deposition in Amyloidosis
Yukio Ando, Kumamoto, Japan
Recognition and Diagnosis of ATTR Cardiomyopathy
Claudio Rapezzi, Bologna, Italy
Management of ATTR Cardiomyopathy
Pablo García-Pavía, Madrid, Spain
Panel Discussion and Q&A
ATTR amyloidosis: Genetics and Basic Science
Chairs:
Merrill D. Benson, Indianapolis, IN, USA
Lawreen H. Connors, Boston, MA, USA
Molecular mechanisms of ATTR amyloidosis
Maria João Saraiva, Porto, Portugal
Driving forces in ATTR amyloidosis
Vittorio BellottiLondon, UK and Pavia, Italy
Genetic signatures associated with hereditary ATTR amyloidosis
Joel BuxbaumLa Jolla, CA, USA
Factors involved in increased susceptibility to TTR amyloidogenesis
Teresa Coelho, Porto, Portugal
Wild-type Transthyretin Amyloidosis – An epidemic hiding in plain sight
Chair:
Pablo García-Pavía, Madrid, Spain
When the bright side of TTR breaks the heart
Maria João Saraiva, Porto, Portugal
Diagnosis and management of wild type TTR amyloidosis
Julian Gillmore, London, UK
Epidemiology and discovery in broader cardiovascular populations
Esther González-López, Madrid, Spain